Guercio V, et al. - Researchers studied 690 bladder cancer cases and 665 hospital controls to examine the connection between bladder cancer risk and the use of selected drugs for cardiovascular disease (CVD) prevention, like aspirin, statins, and calcium channel blockers (CCBs). Findings revealed that there is no relevant association between the use of selected drugs for the prevention of CVD and the risk of bladder cancer, although it suggests a potentially favorable role for CCBs.

Methods

• Between 2003 and 2014, data were analyzed from a multicentric case-control study carried out in Italy.
• Using unconditional multiple logistic regression models, odds ratios (ORs) of bladder cancer and corresponding 95% confidence intervals (CIs) were estimated. 

Results

• According to the findings obtained, the ORs for bladder cancer were 1.21 (95% CI: 0.87–1.68) for regular use of aspirin, 0.72 (95% CI: 0.54–0.97) for use of any CCBs, and 1.32 (95% CI: 0.87–1.99) for use of any statins.
• A slight inverse association with the duration of use of CCBs was found.
• On the other hand, no consistent association was found with duration of use, age at first use, and frequency for aspirin and statin use, or with indication of use for aspirin (as an analgesic or, for CVD prevention).
• There was no significant association for various combinations of drugs or for all drugs combined (OR=1.23, 95% CI: 0.31–4.85).